Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 5/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 1.00 |
| ▸ | CSNK2B | P67870 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | MDH2 | P40926 | 2/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | DNA2 | P51530 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31061216 | 1.00 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BCYP1A2HSD17B10 | |
| SCHEMBL12748348 | 0.75 | CSNK2A2 (0.60) | CSNK2A1CSNK2A2CSNK2BCYP1A2HSD17B10 | |
| SCHEMBL8591175 | 0.74 | CSNK2A2 (0.68) | CSNK2A1CSNK2A2CSNK2BCYP1A2HSD17B10 | |
| SCHEMBL8368785 | 0.74 | CSNK2A2 (0.58) | CSNK2A1CSNK2A2CSNK2BCYP1A2HSD17B10 | |
| SCHEMBL17502115 | 0.72 | CSNK2A2 (1.00) | CSNK2A1CSNK2A2CSNK2BCYP1A2HSD17B10 | |
| SCHEMBL31061407 | 0.72 | CSNK2A2 (1.00) | CSNK2A1CSNK2A2CSNK2BCYP1A2HSD17B10 | |
| SCHEMBL9755991 | 0.72 | CSNK2A2 (0.56) | CSNK2A1CSNK2A2CSNK2BALDH1A1HPGD | |
| SCHEMBL30593848 | 0.72 | CSNK2A2 (0.57) | CSNK2A1CSNK2A2CSNK2BCYP1A2HSD17B10 | |
| SCHEMBL1556273 | 0.72 | CSNK2A2 (0.56) | CSNK2A1CSNK2A2CSNK2BCYP1A2HSD17B10 | |
| SCHEMBL1353252 | 0.72 | CSNK2A2 (0.56) | CSNK2A1CSNK2A2CSNK2BCYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458047-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING MICROBIOME DYSREGULATIONS ASSOCIATED WITH CIRCADIAN CLOCK DISRUPTION | INST NAT SANTE RECH MED (FR) | 2022-08-03 | — | — | EP | disclosed |
| US-11364219-B2 | Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption | INSERM (INSTITUT NATION DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (FR) | 2022-06-21 | — | — | US | disclosed |
| US-20200390740-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING MICROBIOME DYSREGULATIONS ASSOCIATED WITH CIRCADIAN CLOCK DISRUPTION | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-12-17 | — | — | US | disclosed |
| EP-3458047-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING MICROBIOME DYSREGULATIONS ASSOCIATED WITH CIRCADIAN CLOCK DISRUPTION | Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198847-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING MICROBIOME DYSREGULATIONS ASSOCIATED WITH CIRCADIAN CLOCK DISRUPTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11364219-B2 | Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption | PER2, CRY1, CRY2 | CSNK2A1 5/4885CSNK2A2 4/4885CSNK2B 7/4885 |
| US-20200390740-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING MICROBIOME DYSREGULATIONS ASSOCIATED WITH CIRCADIAN CLOCK DISRUPTION | PER2, CRY1, CRY2 | CSNK2A1 5/4885CSNK2A2 4/4885CSNK2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.